Healthcare / Drug Manufacturers - Specialty & GenericJakarta
$3900.00
-110.00 (-2.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $184.0B · quality 65.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
60/100
B
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.75T
P/E
5.9x
↓EV/EBITDA
4.1x
↓ROE
25.0%
↑Gross Margin
47.6%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.2%
FCF CAGR
+58.8%
FCF margin
30.0%
FCF / Net income
1.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.20T · net income $243.90B · FCF $360.65B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1200.67B | $1200.67B | $1036.75B | $961.43B | $1124.60B |
| Net Income | $243.90B | $243.90B | $153.46B | $178.24B | $179.84B |
| EBITDA | $337.95B | $337.95B | $207.79B | $215.92B | $249.82B |
| EPS | — | — | 343.00 | 398.00 | 401.00 |
| Gross Margin | 47.6% | 47.6% | 38.8% | 41.7% | 38.0% |
| Operating Margin | 26.8% | 26.8% | 18.7% | 20.8% | 21.1% |
| Net Margin | 20.3% | 20.3% | 14.8% | 18.5% | 16.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 |
| Current Ratio | 4.91 | 4.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $360.65B | $360.65B | $38.88B | $183.97B | $90.14B |
| Returns | |||||
| ROE | 25.0% | 25.0% | 19.0% | 22.4% | 23.7% |
| Valuation | |||||
| P/E | 5.91 | 5.91 | 10.29 | 10.50 | 11.72 |
| EV/EBITDA | 4.14 | 4.14 | 7.29 | 7.82 | 7.81 |
| P/B | 1.79 | 1.79 | 1.96 | 2.35 | 2.78 |
| Growth & Yield | |||||
| Revenue Growth | 15.8% | 15.8% | 7.8% | -14.5% | — |
| EPS Growth | — | — | -13.8% | -0.7% | — |
| Dividend Yield | 4.4% | 4.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+12.7%
Start / end P/E
n/dx → n/dx
EPS bridge
343.00 → n/d
Residual
+8.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.